Further in cancers that display increased expression of ABCC4 and MPP1 (e.g., breast cancer and medulloblastoma (Supplementary Figs. 7 and 8)), our findings suggest that disrupting the interaction between MPP1 and ABCC4 can improve the cytotoxicity of conventional therapy against tumors. The gene discussed is MPP1; the disease is breast cancer.